Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexza Pharmaceuticals, Inc.
To address the possibility that inhalation of loxapine may have adverse pulmonary effects, we studied two 10-mg inhaled doses of loxapine or placebo were given 10 hr apart to subjects with chronic obstructive pulmonary disease (COPD). The objective was to determine the time course and reversibility of pulmonary effects for inhaled loxapine compared with placebo.
Age
40–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
History of COPD for at least 6 months with pre-bronchodilator FEV1 ≥40% of predicted value and \>15 pack-year history of cigarette smoking.
You may not be if
History of asthma, or any other acute or chronic pulmonary disease.
Clareo Health | Staccato Loxapine Pulmonary Safety in Patients With COPD
